Pharmaceutical Executive-09-13-2005

A look at the science behind a new class of rheumatoid arthritis drugs that act by suppressing an early stage of inflammation, the activation of T cells.

A University of California San Diego professor explains the results of his research on nuclear receptors and why these findings could lead to new therapies for autoimmune diseases.

Analysis of a new report that says safety-related product withdrawals have not increased since the approval process sped up in the 1990s.